Collegium Pharmaceutical: Arus Kas Nyeri Mendanai Re-Rating ADHD (NASDAQ:COLL)
· seekingalpha.com
Collegium Pharma (COLL) beralih ke platform pertumbuhan CNS/ADHD melalui AZSTARYS, menargetkan kenaikan pendapatan/EBITDA tahun 2026; saham tampak undervalued—baca sekarang.
I have a strong inclination towards high-growth companies, often treading in sectors poised for exponential expansion. My expertise lies in understanding and in...